First Patients Enrolled in IMPRoVED-AF Study Using vMap, a Non-Invasive ECG-Based Tool Designed to Guide More Effective AF Ablation
SAN DIEGO, July 09, 2025--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming standard ECG data into actionable insights that guide arrhythmia care, today announced that Baptist Health Lexington has enrolled the first patients in the IMPRoVED-AF clinical study. Baptist Health Lexington, a 434-bed acute care hospital, is a long-time leader in innovative approaches to treat heart disease and related conditions.
IMPRoVED-AF is a prospective, randomized, controlled, international, multi-center study designed to rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by vMap®, the only FDA-cleared non-invasive arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. The study aims to demonstrate the comparative clinical benefit of using vMap to identify and ablate non-pulmonary vein electrical drivers, when used alongside standard-of-care ablation techniques, including advanced technologies such as pulsed field ablation (PFA), in patients with persistent and recurrent atrial fibrillation (AF).
"Enrolling the first patient in the IMPRoVED-AF study marks an important milestone in our ongoing efforts at Baptist Health to further advance care for our patients suffering from cardiac arrhythmias," said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. "For patients with persistent and recurrent AF, treatment has often been ineffective due to the inability to identify the source of the arrhythmia. Using vMap to determine a targeted ablation strategy beyond the pulmonary veins provides an opportunity to target drivers that were previously undetectable. That means better care and more effective, lasting results for patients."
With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need by delivering rapid analysis and insights from a standard 12-lead ECG.
"The IMPRoVED-AF study is an important validation of the meaningful impact vMap is already delivering in the EP lab," said Rob Krummen, CEO of Vektor Medical. "This isn't about incremental improvement; it's a leap forward in how we identify and treat complex arrhythmias. vMap is uncovering drivers that often go undetected, helping physicians deliver more effective and durable outcomes. This study is a critical part of our strategy to build the clinical evidence that drives confident adoption, supports value in health systems, and positions vMap as the new standard in arrhythmia care."
The IMPRoVED-AF study, managed by Veranex, a global leader in clinical research, will enroll up to 384 patients with persistent and recurrent AF at approximately 20 electrophysiology centers across the United States and Europe. The primary endpoint of the study is freedom from AF at 12 months.
To learn more about the IMPRoVED-AF study, explore vMap technology, or request a clinical or strategic briefing, visit www.vektormedical.com and connect with us on LinkedIn and X.
About vMap®
vMap is the only FDA-cleared, non-invasive solution that transforms data from a standard 12-lead ECG into actionable insights to guide arrhythmia care. The technology, developed with AI, localizes arrhythmia source locations across all four chambers of the heart — including both focal and fibrillation-type arrhythmias. vMap is used by electrophysiologists during triage, procedural planning, and ablation to help identify and target arrhythmia drivers more quickly and with greater confidence. Backed by growing clinical evidence, use of vMap has been associated with improved outcomes, reduced procedure time, and streamlined workflow across the arrhythmia care continuum.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is working to improve outcomes, enhance efficiencies, and accelerate access to effective treatment strategies. To learn more, visit www.vektormedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250709915203/en/
Contacts
Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@levitatenow.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ('Amylyx' or the 'Company') today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squares (LS) mean reduction (p=0.0031) vs. baseline in the composite rate of Level 2 and Level 3 hypoglycemic events in PBH, with more than half of the participants experiencing no events during the treatment period. LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass surgery. The FDA-agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events. Consistent reductions in composite rate of Level 2 and Level 3 hypoglycemic events also were seen with avexitide 45 mg twice daily studied in the Phase 2b trial and avexitide 30 mg twice daily and 60 mg once daily studied in the Phase 2 PREVENT trial. New pharmacokinetic (PK) and pharmacodynamic (PD) data were also presented demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period. 'Post-bariatric hypoglycemia can profoundly disrupt daily life, requiring individuals to carefully manage meals, social interactions, and routines, often while living in fear of their next hypoglycemic event. The new analysis presented at ENDO 2025 continues to support that avexitide may significantly reduce the frequency of these events,' said Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY trial and Clinical Associate Professor at Stanford University. Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, added, 'Post-bariatric hypoglycemia is a serious and underrecognized condition with no FDA-approved treatments. The data presented show that, in an exploratory analysis from the Phase 2 PREVENT and Phase 2b clinical trials, avexitide significantly reduced the composite rate of Level 2 and 3 hypoglycemic events, including at the 90 mg once daily dose that is being studied in our pivotal Phase 3 LUCIDITY trial. We are particularly encouraged that over half of participants did not experience Level 2 or Level 3 hypoglycemic events during the treatment period. In addition, the pharmacokinetic and pharmacodynamic data demonstrated continuous pharmacologic activity of avexitide 90 mg once daily dose over 24 hours. We continue to be encouraged by avexitide's potential to deliver consistent, meaningful benefit to people living with PBH.' The population PK and PD analyses presented at ENDO 2025 demonstrated that avexitide 90 mg once daily maintained consistent GLP-1 receptor inhibition from morning to midnight and between doses. In vitro potency studies showed an IC₅₀ of approximately 20-30 nM (70-100 ng/mL), indicating robust target inhibition even in the presence of significant levels of GLP-1. PK modeling demonstrated that avexitide plasma levels exceeded IC₅₀ for a full 24-hour period. LUCIDITY was informed by data from five PBH clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant and clinically meaningful reductions in hypoglycemic events. Avexitide was generally well-tolerated, with a favorable safety profile replicated across clinical trials. Completion of recruitment for LUCIDITY is expected in 2025, with a data readout anticipated in the first half of 2026 and, if approved, commercial launch anticipated in 2027. The presentation and posters are available on the ' Presentations ' tab of the Amylyx website. Webcast Information Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco to discuss post-bariatric hypoglycemia and avexitide. A live webcast of the presentation and Q&A portion of the event can be accessed under 'Events and Presentations' in the Investor section of the Company's website, The webcast will be archived and available for replay for 90 days following the event. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About Post-Bariatric Hypoglycemia (PBH) Post-bariatric hypoglycemia (PBH) is a condition that is estimated to affect approximately 8% of people in the U.S. who have undergone the two most common types of bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass (approximately 160,000 people in the U.S.). PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About the LUCIDITY Trial LUCIDITY (NCT06747468) is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial includes an up to six-week screening period, including a three-week run-in period, and a 16-week double-blind treatment period. Participants who complete the double-blind period will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit and follow us on LinkedIn and X. For investors, please visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx' expectations regarding: the potential of avexitide as a treatment for PBH; expectations regarding the timing for recruitment completion and topline data readout of the Phase 3 LUCIDITY trial of avexitide in PBH; and expectations regarding timing for potential commercialization of avexitide. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx' program development activities; Amylyx' ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx' ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx' operations, as well as the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, including Amylyx' Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Yahoo
3 hours ago
- Yahoo
Coca-Cola hit with massive recall as popular product is possibly contaminated: 'All impacted product has been removed from store shelves'
A recall of Coca-Cola-owned Topo Chico mineral water for possible contamination received a Class II risk assignment from the U.S. Food and Drug Administration in June. As Newsweek reported, Coca-Cola issued the limited recall on May 28, and the FDA assigned the risk classification on June 17. The FDA has three recall classes. A Class II recall is a situation in which exposure to the product can "cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." The Topo Chico recall occurred because of a potential contamination with Pseudomonas bacteria. This class of bacteria is commonly found in the environment, though a certain type can lead to "infections in the blood, lungs, urinary tract, or other parts of the body after surgery," according to guidance from the Centers for Disease Control and Prevention cited by Newsweek. The recall concerned 241 cases of Topo Chico Mineral Water distributed across five states: Arizona, Louisiana, Nevada, New Mexico, and Texas. Around 40 stores sold the water, including some Costco and Sam's Club locations, Fox Business reported. A spokesperson for Coca-Cola told Newsweek in mid-June that "all impacted product has been removed from store shelves." As of June 25, there were "no illnesses or adverse reactions," reported Food Safety News, though the recall remained active. Consumers who bought the affected 16.9-fluid-ounce bottles were asked to return or discard the product without drinking it. Food recalls are a crucial tool for regulators, companies, and consumers to help protect public health. In the Topo Chico case, Coca-Cola initiated a voluntary product removal in the public's best interest after a distributor informed the corporation about a concern. Viewed broadly, Coca-Cola has a more questionable record regarding its impact on human health and the planet. The company has consistently made the list of World's Worst Plastic Polluters based on audits by the Break Free From Plastic organization. In 2024, Coca-Cola was the largest known producer of branded plastic waste in the world, according to a study reported on by Axios. The production and use of plastic are problematic for various reasons, ranging from microplastic health risks — particularly in plastic-bottled beverages — to the generation of heat-trapping gases that warm the planet. How often do you worry about the quality of your drinking water? Never Sometimes Often Always Click your choice to see results and speak your mind. And, of course, there are complex issues about the nutritional effects of the company's many products. Topo Chico products are packaged in glass and occasionally aluminum, which Coca-Cola correctly touts as more recyclable than plastic. The company also promotes the health benefits of Topo Chico and other products, as well as its overall sustainability goals. Coca-Cola has achieved success in reducing plastic ring packaging, and it has prioritized water replenishment programs to restore usable water to communities. Yet critics have accused Coke of "greenwashing" — making pledges for sustainability efforts that it does not live up to or later retracts, such as when it walked back a commitment to reusable packaging, The Guardian reported. Meanwhile, the complexities of ensuring safe and uncontaminated drinking water are not a problem limited to Coca-Cola — critics have called for improving research and regulation in this area, as well. For consumers concerned about health and the environment, it's important to be aware of and responsive to food recalls, to think critically about companies' health claims and efforts, and to support brands that reduce plastic packaging. To save money while reducing microplastic concerns, consumers can also switch to reusable bottles made of non-plastic materials. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Newsweek
13 hours ago
- Newsweek
FDA Issues Risk Warning After Mushrooms Recalled Nationwide
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has issued a national advisory and classified a recent mushroom recall as Class I, the agency's highest level risk designation, due to potential Listeria monocytogenes contamination. Newsweek contacted Hofood99 Inc via telephone for comment outside of usual working hours on Sunday and left a voicemail message. Why It Matters The Class I recall status indicates that the product poses a risk of causing serious health consequences or death if consumed. Listeria monocytogenes can lead to severe and sometimes fatal infections, especially during pregnancy, and for newborns, elderly adults, and people with weakened immune systems. Although no illnesses have been reported, the risk to public health is significant, prompting the warnings from the FDA. This incident highlights ongoing concerns surrounding food safety, especially in the distribution and handling of perishable produce. What to Know As reported by Newsweek, the firm-initiated recall affects enoki mushrooms distributed by Hofood99 Inc, located at 21903 56th Avenue Oakland Gardens, New York, 11364. The affected mushrooms were sold in 200‑gram green plastic bags and marked with UPC 6 976532 310051 on the back label; a picture of enoki mushrooms is outlined in green on the front of the package. The recall number is H-0261-2025. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) The 90 boxes of affected product were shipped to retailers nationwide and tested positive for Listeria during routine sampling conducted by the Michigan Department of Agriculture. Consumers are advised not to eat the product and to either discard it or return it to the store where it was purchased for a full refund. Symptoms of Listeria infection may include high fever, muscle aches, nausea, diarrhoea, and in severe cases, complications such as meningitis or miscarriage. Consumers are advised to clean and sanitise refrigerators and any surfaces that may have come into contact with the recalled mushrooms, as the bacteria can survive and spread in cold environments. What People Are Saying The FDA in the original alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." The FDA, as stated on its website: "A recall is a method of removing or correcting products that are in violation of laws administered by the Food and Drug Administration (FDA). Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective. What Happens Next Consumers with questions can contact Hofood99 Inc. at (917) 756‑9833 during business hours of 9:00 a.m. to 2:00 p.m., Monday to Friday. Further updates are available on the FDA's website. Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts.
